<DOC>
	<DOCNO>NCT00061581</DOCNO>
	<brief_summary>Bone marrow transplantation ( BMT ) risky procedure . If doctor could reduce complication , BMT would safer use wider range condition . The purpose study - prevent graft rejection increase amount immunosuppression give lymphocyte donor transplant ; - prevent graft-versus-host disease ( GVHD ) transplant T-cell depleted stem cell ; - improve immune effect residual leukemia add-back donor lymphocyte transplant six week transplant . Beyond standard transplant protocol , study participant undergo additional procedure . First , along total body irradiation , patient receive two drug ( high dose cyclophosphamide fludarabine ) suppress immunity prevent rejection transplant . Second , four day transplant , patient give donor lymphocyte irradiate make incapable cause GVHD . On day transplant , patient receive infusion T-cell deplete bone marrow stem cell . Finally , patient receive two dos add-back donor T-cells ( 45 100 day post transplant ) immunosuppressive drug cyclosporine start day 44 six month transplant . Study participant must age 10 56 family member suitable stem cell donor match .</brief_summary>
	<brief_title>Experimental Bone Marrow Transplant Protocol</brief_title>
	<detailed_description>Stem cell transplant study carry NHLBI BMT Unit focus approach optimize stem cell lymphocyte dose order improve transplant survival increase graft-vs.-leukemia effect . The aim create transplant condition permit rapid donor immune recovery without cause graft-versus-host disease ( GVHD ) use post-transplant immunosuppression conjunction transplant deplete T cell fix low dose , threshold know associated GVHD . We find outcome transplant improve controlling stem cell ( CD34+ cell ) T lymphocyte ( CD3+ cell ) dose . In last study , series , use Nexell Isolex 300i system obtain high CD34+ dos deplete lymphocyte fix CD3+ T cell dose 2 x 10 ( 4 ) /kg . The use cell separator monoclonal antibody cover IDE 8139 . The study measure incidence acute GVHD use chimerism assay determine percentage donor recipient cell circulate different time-points transplant . We find first six week donor T cell chimerism vary widely reach 100 % 10/22 patient . Thus goal rapid donor immune recovery achievable half patient . Patients mixed donor-recipient T cell population know high risk late graft rejection leukemic relapse transplant . Therefore achievement full donor chimerism important therapeutic goal . To improve donor T cell chimerism test whether addition irradiate donor lymphocytes preparative regimen transplant increase chance achieve 100 % donor T cell chimerism within six week transplant . It known irradiated lymphocyte cause GVHD suppress residual host immunity , thus promote donor lymphocyte engraftment . The end point study proportion patient achieve full donor chimerism six week transplant . Apart addition irradiate lymphocyte minor modification , protocol identical predecessor protocol 02-H-0111 . This involve continue use Isolex 300i cell separator monoclonal antibody provide CTEP ( anti CD 6 , anti CD2 , anti CD7 ) . This cover continue IND selection CD34+ CD3+ cell T cell deplete peripheral blood stem cell transplantation .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>INCLUSION CRITERIA FOR RECIPIENTS : Recipient Ages 1055 year inclusive ( less 56 ) Chronic myelogenous leukemia chronic phase A ) Patients treat STI 571 age 41 ( subject regular DSMB review ) . B ) 1055 age limit patient chronic phase fail treatment STI571 . C ) 1055 age limit patient accelerated phase blast transformation . Acute lymphoblastic leukemia , category : Adults ( great 18 year ) first remission highrisk feature ( present leukocyte count great 100,000/cu mm , Karyotypes t9 ; 22 , t4 , t19 , t11 , biphenotypic leukemia ) All second subsequent remission , primary induction failure , partially respond untreated relapse . Acute myelogenous leukemia ( AML ) : AML first remission Except AML good risk karyotype : AML M3 ( t15 ; 17 ) , AML M4Eo ( inv 16 ) , AML ( 8 ; 21 ) . All AML second subsequent remission , primary induction failure resistant relapse . Myelodysplastic syndrome , category : refractory anemia transfusion dependence , refractory anemia excess blast , transformation acute leukemia , chronic myelomonocytic leukemia . Myeloproliferative disorder ( myelofibrosis , polycythemia vera , essential thrombocythemia ) transformation acute leukemia Chronic lymphocytic leukemia refractory fludarabine treatment bulky progressive disease thrombocytopenia ( less equal 100,000/ml ) anemia ( less equal 10g/dl ) due recent chemotherapy . NonHodgkin lymphoma include Mantle cell lymphoma relapse refractory current chemotherapy monoclonal antibody treatment unsuitable autologous stem cell transplantation . No major organ dysfunction preclude transplantation . DLCO great equal 60 % predict . Left ventricular ejection fraction : great equal 40 % predict . ECOG performance status 0 1 . For adult : Ability comprehend investigational nature study provide inform consent . For minor : Written inform consent one parent guardian . Informed oral consent minor : The process explain minor level complexity appropriate age ability comprehend . Negative pregnancy test woman childbearing age . INCLUSION CRITERIA FOR DONORS : HLA 6/6 identical family donor Weight great equal 18 kg Age great equal 2 less equal 80 year old Fit receive GCSF give peripheral blood stem cell ( normal blood count , normotensive , history stroke ) For adult : Ability comprehend investigational nature study provide inform consent . For minor : Written inform consent one parent guardian inform assent : The process explain minor level complexity appropriate age ability comprehend . EXCLUSION CRITERIA FOR RECIPIENTS ( follow ) : Patient pregnant Age le 10 year 56 year Patients CML chronic phase 41 year STI 571 treatment choice ECOG performance status 2 Severe psychiatric illness . Mental deficiency sufficiently severe make compliance BMT treatment unlikely , make informed consent impossible . Major anticipated illness organ failure incompatible survival BMT DLCO le 60 % predict . Left ventricular ejection fraction : le 40 % predict Serum creatinine great 3mg/dl Serum bilirubin great 4 mg/dl Transaminases great 3 time upper limit normal HIV positive History malignancy except basal cell squamous carcinoma skin , positive PAP smear subsequent negative follow , individual disease list eligibility criterion protocol , debility age make risk intensive myeloablative therapy unacceptable . This include patient receive busulfan treatment 6 month continuously . These patient consider nonmyeloablative allogeneic transplantation protocol . EXCLUSION CRITERIA : Donor ( follow ) Pregnant lactate Donor unfit receive GCSF undergo apheresis . ( Uncontrolled hypertension , history congestive heart failure unstable angina , thrombocytopenia ) HIV positive . Donors positive HBV , HCV HTLV1 may use riskbenefit ratio consider acceptable patient investigator . Weight le 18 kg Age le 2 great 80 year Severe psychiatric illness . Mental deficiency sufficiently severe make compliance BMT treatment unlikely , make informed consent impossible</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 14, 2016</verification_date>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Acute Myelogenous Leukemia ( AML )</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Graft-Versus Leukemia/Myeloma</keyword>
	<keyword>Graft-Versus-Host Disease</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Myelodysplasia Syndrome</keyword>
</DOC>